RecruitingPHASE1, PHASE2NCT07022964
CD5 CAR T-Cell Therapy for r/r T-cell Lymphomas
Studying Aggressive primary cutaneous T-cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Beijing GoBroad Hospital
- Principal Investigator
- Tengyu Wang, Ph.DBeijing GoBroad Hospital, Beijing, Beijing 102200
- Intervention
- CD5 CAR-T cells infusion(drug)
- Enrollment
- 36 enrolled
- Eligibility
- 14-70 years · All sexes
- Timeline
- 2025 – 2028
Study locations (3)
- Beijing GoBroad Hospital, Beijing, China
- Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
- Shanghai Liquan Hospital, Shanghai, China
Collaborators
Ruijin Hospital · Shanghai Liquan Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07022964 on ClinicalTrials.govOther trials for Aggressive primary cutaneous T-cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT05544968Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic MalignanciesMedical College of Wisconsin
- RECRUITINGPHASE1NCT07055477A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)National Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07047885Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)H. Lee Moffitt Cancer Center and Research Institute
- RECRUITINGNANCT06860880Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramUNC Lineberger Comprehensive Cancer Center
- RECRUITINGNCT07132567Assessment of Safety and Efficacy of Poteligeo Inj. 20 mg (Mogamulizumab) Through Use-result SurveillanceKyowa Kirin Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT06925464CD7 CAR T-Cell Therapy for r/r T-cell LymphomasBeijing GoBroad Hospital
- RECRUITINGPHASE1NCT06914037A Clinical Study of CHT101 in CD70-Positive Relapsed or Refractory Hematological MalignanciesTianjin Medical University Cancer Institute and Hospital
- RECRUITINGPHASE2NCT06854653A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCLPrescient Therapeutics, Ltd.
See all trials for Aggressive primary cutaneous T-cell lymphoma →